These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 31432366)

  • 1. Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse.
    Siddappa CM; Pillai SG; Snider J; Alldredge P; Trinkaus K; Watson MA; Aft R
    Breast Cancer Res Treat; 2019 Nov; 178(2):317-325. PubMed ID: 31432366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of disseminated tumor cells in the bone marrow of breast cancer patients using multiplex gene expression measurements identifies new therapeutic targets in patients at high risk for the development of metastatic disease.
    Siddappa CM; Watson MA; Pillai SG; Trinkaus K; Fleming T; Aft R
    Breast Cancer Res Treat; 2013 Jan; 137(1):45-56. PubMed ID: 23129172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
    Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L
    Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model.
    Pillai SG; Li S; Siddappa CM; Ellis MJ; Watson MA; Aft R
    Breast Cancer Res; 2018 Jan; 20(1):2. PubMed ID: 29291741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
    Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
    Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer.
    Liu YR; Jiang YZ; Xu XE; Hu X; Yu KD; Shao ZM
    Clin Cancer Res; 2016 Apr; 22(7):1653-62. PubMed ID: 26813360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disseminated tumor cells from the bone marrow of patients with nonmetastatic primary breast cancer are predictive of locoregional relapse.
    Hartkopf AD; Wallwiener M; Fehm TN; Hahn M; Walter CB; Gruber I; Brucker SY; Taran FA
    Ann Oncol; 2015 Jun; 26(6):1155-1160. PubMed ID: 25791636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome.
    Tjensvoll K; Oltedal S; Heikkilä R; Kvaløy JT; Gilje B; Reuben JM; Smaaland R; Nordgård O
    BMC Cancer; 2012 May; 12():190. PubMed ID: 22640166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes.
    Lee HJ; Lee JJ; Song IH; Park IA; Kang J; Yu JH; Ahn JH; Gong G
    Breast Cancer Res Treat; 2015 Jun; 151(3):619-27. PubMed ID: 26006068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain Metastasis Prediction by Transcriptomic Profiling in Triple-Negative Breast Cancer.
    Duchnowska R; Jarząb M; Żebracka-Gala J; Matkowski R; Kowalczyk A; Radecka B; Kowalska M; Pfeifer A; Foszczyńska-Kłoda M; Musolino A; Czartoryska-Arłukowicz B; Litwiniuk M; Surus-Hyla A; Szabłowska-Siwik S; Karczmarek-Borowska B; Dębska-Szmich S; Głodek-Sutek B; Sosińska-Mielcarek K; Chmielowska E; Kalinka-Warzocha E; Olszewski WP; Patera J; Żawrocki A; Pliszka A; Tyszkiewicz T; Rusinek D; Oczko-Wojciechowska M; Jassem J; Biernat W;
    Clin Breast Cancer; 2017 Apr; 17(2):e65-e75. PubMed ID: 27692773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict clinical outcome in operable breast cancer patients.
    Tjensvoll K; Oltedal S; Farmen RK; Shammas FV; Heikkilä R; Kvaløy JT; Gilje B; Smaaland R; Nordgård O
    Clin Breast Cancer; 2010 Oct; 10(5):378-84. PubMed ID: 20920982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis.
    Hartkopf AD; Taran FA; Wallwiener M; Hahn M; Becker S; Solomayer EF; Brucker SY; Fehm TN; Wallwiener D
    Eur J Cancer; 2014 Oct; 50(15):2550-9. PubMed ID: 25096167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paired-like Homeodomain Transcription factor 2 expression by breast cancer bone marrow disseminated tumor cells is associated with early recurrent disease development.
    Pillai SG; Dasgupta N; Siddappa CM; Watson MA; Fleming T; Trinkaus K; Aft R
    Breast Cancer Res Treat; 2015 Oct; 153(3):507-17. PubMed ID: 26400846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.
    Giuliano M; Herrera S; Christiny P; Shaw C; Creighton CJ; Mitchell T; Bhat R; Zhang X; Mao S; Dobrolecki LE; Al-rawi A; Chen F; Veneziani BM; Zhang XH; Hilsenbeck SG; Contreras A; Gutierrez C; Jeselsohn RM; Rimawi MF; Osborne CK; Lewis MT; Schiff R; Trivedi MV
    Breast Cancer Res; 2015 Jan; 17(1):3. PubMed ID: 25572662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Expression of Circulating MicroRNA-34c is Associated with Poor Prognosis in Triple-Negative Breast Cancer.
    Zeng Z; Chen X; Zhu D; Luo Z; Yang M
    Yonsei Med J; 2017 Jul; 58(4):697-702. PubMed ID: 28540980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
    Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression in triple-negative breast cancer in relation to survival.
    Wang S; Beeghly-Fadiel A; Cai Q; Cai H; Guo X; Shi L; Wu J; Ye F; Qiu Q; Zheng Y; Zheng W; Bao PP; Shu XO
    Breast Cancer Res Treat; 2018 Aug; 171(1):199-207. PubMed ID: 29748761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Analysis of Disseminated Tumor Cells (DTCs) and Circulating Tumor DNA (ctDNA) in a Patient Suffering from Triple Negative Breast Cancer Revealed Elevated Risk.
    Nel I; Herzog H; Aktas B
    Front Biosci (Landmark Ed); 2022 Jun; 27(7):208. PubMed ID: 35866394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a.
    He R; Liu P; Xie X; Zhou Y; Liao Q; Xiong W; Li X; Li G; Zeng Z; Tang H
    J Exp Clin Cancer Res; 2017 Oct; 36(1):145. PubMed ID: 29037220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.